Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Patients With Advanced Solid Tumors

NCT07337525 is registered in ClinicalTrials.gov with Pilatus Biosciences Inc as lead sponsor.

NCT NCT07337525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Patients With Advanced Solid Tumors
Lead sponsor
Pilatus Biosciences Inc
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2026
Completion date
January 31, 2028
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor, solid tumor cancer